Effects of Pharmacokinetic Gene Variation on Therapeutic Drug Levels and Antidepressant Treatment Response

Discussion The present data support previous recommendations to reduce
starting doses of amitriptyline and to guide dose-adjustments via therapeutic
drug monitoring in CYP2D6 poor metabolizers. In addition, we propose including
CYP2C19 in routine testing in venlafaxine-treated patients to improve
therapy by raising awareness of the risk of low serum concentrations in CYP2C19
rapid/ultrarapid metabolizers. In summary, pk gene variation can predict
serum concentrations, and thus the combination of pharmacogenetic testing and
therapeutic drug monitoring is a useful tool in a personalized therapy approach
for depression. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents  |  Abstract  |  open access Full text

Source: Pharmacopsychiatry - July 15, 2022 Category: Psychiatry Authors: Scherf-Clavel, Maike Weber, Heike Wurst, Catherina Stonawski, Saskia Hommers, Leif Unterecker, Stefan Wolf, Christiane Domschke, Katharina Rost, Nicolas Br ückl, Tanja Lucae, Susanne Uhr, Manfred Binder, Elisabeth B. Menke, Andreas Deckert, J ürgen Tags: Original Paper Source Type: research